JNJ Latest Headlines

Analysts Are Bullish on These Healthcare Stocks: Omeros (OMER), Johnson & Johnson (JNJ)

at www.tipranks.com (Wed, 14-Oct 7:50 AM)

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Revolution Medicines (RVMD) and Viridian Therapeutics (VRDN)

at www.tipranks.com (Wed, 14-Oct 6:50 AM)

J&J Buy Rating Reiterated as Long-Term Pipeline Strength Supports Outlook; $294 Price Target Unchanged

at www.tipranks.com (Wed, 14-Oct 6:36 AM)

Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), United Therapeutics (UTHR) and Johnson & Johnson (JNJ)

at www.tipranks.com (Wed, 14-Oct 6:30 AM)

Analysts Have Conflicting Sentiments on These Healthcare Companies: Johnson & Johnson (JNJ) and Liquidia Technologies (LQDA)

at www.tipranks.com (Wed, 14-Oct 5:50 AM)

Analysts Conflicted on These Healthcare Names: UnitedHealth (UNH), BrightSpring Health Services, Inc. (BTSG) and Johnson & Johnson (JNJ)

at www.tipranks.com (Wed, 14-Oct 5:30 AM)

JNJ Highlights 3-Year TREMFYA Data With Up to 94% Clinical Remission in Crohn’s Disease

Market Chameleon (Tue, 13-Oct 11:18 AM)

Johnson & Johnson sets $1.34 quarterly dividend with November 24 ex-dividend date

Market Chameleon (Tue, 13-Oct 7:08 AM)

Johnson & Johnson Earnings Call: Growth Amid Headwinds

at www.tipranks.com (Tue, 13-Oct 8:02 PM)

Stocks making big moves after hours: BAC, KNDI, C

at seekingalpha.com (Tue, 13-Oct 4:40 PM)

3 ETFs Tipped for 10% or More Gains by AI Analyst

at www.tipranks.com (Tue, 13-Oct 3:02 PM)

Why SpaceX and J&J Stocks Are Falling Today — and What Wall Street Sees Next

at www.tipranks.com (Tue, 13-Oct 1:44 PM)

Johnson & Johnson leaning toward spinning out hips-and-knees business - WSJ

at seekingalpha.com (Tue, 13-Oct 1:18 PM)

J&J shares down despite guidance raise as MedTech revenues disappoint

at seekingalpha.com (Tue, 13-Oct 12:04 PM)

FDA Greenlights First-ever Therapy for Warm Autoimmune Hemolytic Anemia – J&J’s IMAAVY Redefines the Treatment Landscape

Market Chameleon (Tue, 25-Aug 7:08 AM)

Johnson & Johnson Signals Strategic Interest in Psychiatric Treatment Innovation with $14.6 Billion Deal

Market Chameleon (Thu, 6-Aug 9:47 AM)

Johnson & Johnson Expands Oncology Pipeline with $1B Firefly Bio Acquisition—Targeting Hard-to-Treat Cancers

Market Chameleon (Thu, 30-Jul 7:40 AM)

Johnson & Johnson Moves to End Talc Litigation With $5.5 Billion Proposed Settlement

Market Chameleon (Tue, 28-Jul 7:09 AM)

Johnson & Johnson Confirms $1.34 Dividend for Q3 2026—Signals Stability and Shareholder Confidence

Market Chameleon (Wed, 15-Jul 7:08 AM)